Archives
-
Pretomanid Targets Both TB Terminal Oxidases
2026-09-15
The reference study shows that pretomanid inhibits both cytochrome bcc:aa3 and cytochrome bd terminal oxidase branches in Mycobacterium tuberculosis. This dual respiratory mechanism explains synergy with telacebec and supports combination regimens designed to improve bactericidal activity while limiting resistance.
-
Targeted BRD7 Demethylation in Nasopharyngeal Carcinoma
2026-09-15
The reference study shows that hypermethylation of the BRD7 promoter suppresses a tumor-suppressive program in nasopharyngeal carcinoma (NPC). By directing dCas9-TET1 catalytic activity to selected promoter sites, the authors reactivated BRD7 and reduced malignant progression, with combined sgRNA2 and sgRNA5 producing the strongest reported effect.
-
Precision PCR for CRISPR Immunotherapy Translation
2026-09-14
A thought-leadership analysis of how high-fidelity PCR can strengthen translational workflows inspired by bufalin–CRISPR nanomedicine research in colorectal cancer. The article connects immune mechanism, construct integrity, blunt-end cloning, assay reproducibility, and strategic experimental design while positioning 2X HyperFusion™ High-Fidelity Master Mix as an enabling technology rather than a substitute for biological validation.
-
Influenza A NEP Constraints from Mutational Scanning
2026-09-14
A 2025 Cell Reports study used deep mutational scanning to measure the replication effects of more than 1,800 single-amino-acid mutations in influenza A virus nuclear export protein (NEP). The work shows that the apparently disordered N-terminal domain is unusually mutation-tolerant but still influences viral RNA synthesis, host responses, and mammalian adaptation, revealing functional constraints that sequence conservation alone cannot resolve.
-
Ciclesonide B3477 for Reliable Cell Assays
2026-09-13
Learn how Ciclesonide (SKU B3477) can improve experimental control in respiratory cell models by separating prodrug activation, glucocorticoid receptor binding, solvent handling, and biological interpretation. This scenario-driven guide links quantitative product data with practical assay design while clearly distinguishing established respiratory pharmacology from emerging ERAD research.
-
Itraconazole: Mechanism, Biofilm Evidence, and Use
2026-09-12
Itraconazole is a triazole antifungal agent with activity against selected Candida species and important CYP3A4 interaction properties. This article separates direct itraconazole evidence from mechanistic evidence on Candida biofilm resistance and PP2A-regulated autophagy.
-
Paclitaxel (Taxol): Workflow for Cancer Research
2026-09-11
Build more interpretable cancer assays with Paclitaxel (Taxol), from solvent-controlled microtubule stabilization to G2-M profiling and combination studies. A FOXM1-focused reference study adds a practical framework for testing whether pathway suppression can sensitize resistant models to paclitaxel.
-
Ciclesonide Assays: From Prodrug to ERAD Insight
2026-09-11
Ciclesonide provides a powerful model for linking prodrug activation, glucocorticoid receptor binding, and lung-cell pharmacology. This article adds an assay-design framework that distinguishes validated respiratory biology from the emerging ERAD platform reported for desonide-based degraders.
-
SP600125: A Practical JNK Inhibitor Workflow
2026-09-10
SP600125 enables mechanism-focused interrogation of JNK signaling in cytokine, inflammation, and stress-response assays. This guide connects the CPSIT_0844–TLR2/TLR4 study to practical inhibitor workflows, controls, readouts, and troubleshooting strategies.
-
KPT-330: Reading XPO1–Platinum Synergy
2026-09-10
KPT-330 (Selinexor) links CRM1/XPO1 nuclear-export biology with platinum sensitivity. This evidence-led guide explains how recent DLBCL findings should shape mechanistic assays, controls, and interpretation in cancer research.
-
ATRX-Deficient Glioma and RTK Inhibitor Sensitivity
2026-09-09
The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. It also shows that combining these inhibitors with Temozolomide increases toxicity in ATRX-deficient models, supporting ATRX-aware design and interpretation of glioma drug studies.
-
Tetraethylammonium Chloride as a Causal Probe
2026-09-09
Tetraethylammonium chloride (TEAC) is more than a potassium-channel blocker: it is a causal probe for separating ion-conduction effects from downstream physiology. This article explains how to design, interpret, and limit TEAC experiments across electrophysiology, vascular research, and translational pharmacology.
-
Interpretable Radiopathomics for Gastric Cancer Immunotherap
2026-09-08
A multicenter study developed an interpretable radiopathomics signature by integrating baseline CT images with digital H&E pathology to predict response to immunotherapy-based combination therapy in gastric cancer. The signature showed strong discrimination across internal and external cohorts and was associated with immune-regulatory biology, suggesting a route toward multimodal treatment stratification while requiring further prospective validation.
-
Resazurin sodium salt in iPSC-CF Assays
2026-09-08
Resazurin sodium salt converts cellular redox activity into a fluorescence-compatible readout that can complement advanced cystic fibrosis iPSC models. This guide connects practical plate, imaging, flow cytometry, and screening workflows with controls that prevent metabolic signal from being mistaken for direct CFTR function.
-
Tunable Human Intestinal Organoids: Study Insights
2026-09-07
This Nature Communications study develops a human small intestinal organoid system that maintains high proliferation while expanding cellular diversity under a single culture condition. Its central innovation is the use of pathway modulation to strengthen stemness and then reversibly or directionally tune differentiation without recreating artificial spatial signaling gradients.